<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399626</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1016-1430</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Medical journal of the Islamic Republic of Iran</Title><ISOAbbreviation>Med J Islam Repub Iran</ISOAbbreviation></Journal><ArticleTitle>Age-Adjusted in-Hospital Mortality in Patients with COVID-19 Infection: Impact of the Presence of Multiple Comorbidities.</ArticleTitle><Pagination><StartPage>60</StartPage><MedlinePgn>60</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">60</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.47176/mjiri.38.60</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Mortality has been indicated to be high in patients with underlying diseases. This study aimed to examine the comorbidities is associated with a higher risk of death during the hospital course.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We retrospectively evaluated the risk of in-hospital death in 1368 patients with COVID-19 admitted to 5 academic hospitals in Tehran between February 20 and June 13, 2020. We also assessed the composite end-point of intensive care unit admission, invasive ventilation, and death. The Cox proportional survival model determined the potential comorbidities associated with deaths and serious outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The retrospective follow-up of patients with COVID-19 over 5 months indicated 280 in-hospital deaths. Patients with diabetes (risk ratio (RR), 1.47 (95% CI, 1.10-1.95); <i>P</i> = 0.008) and chronic kidney disease (RR, 1.72 (95% CI, 1.16-2.56); <i>P</i> = 0.007) showed higher in-hospital mortality. Upon stratifying data by age, patients aged ˂65 years showed a greater risk of in-hospital death in the presence of 2 (hazard ratio (HR), 2.68 (95% CI, 1.46-4.95); <i>P</i> = 0.002) or more (HR, 3.47 (95% CI, 1.69-7.12); <i>P</i> = 0.001) comorbidities, compared with those aged ≥ 65 years.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Having ≥ 2 comorbidities in nonelderly patients is associated with a greater risk of death during hospitalization. To reduce the mortality of COVID-19 infection, younger patients with underlying diseases should be the focus of attention for prevention strategies.</AbstractText><CopyrightInformation>© 2024 Iran University of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>Nader</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemi-Madani</LastName><ForeName>Nahid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malek</LastName><ForeName>Mojtaba</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emami</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khajavi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghili</LastName><ForeName>Rokhsareh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honardoost</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdolmaleki</LastName><ForeName>Fereshteh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>E Khamseh</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4313-8440</Identifier><AffiliationInfo><Affiliation>Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Med J Islam Repub Iran</MedlineTA><NlmUniqueID>8910777</NlmUniqueID><ISSNLinking>1016-1430</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Invasive Ventilation</Keyword><Keyword MajorTopicYN="N">Iran</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399626</ArticleId><ArticleId IdType="pmc">PMC11469712</ArticleId><ArticleId IdType="doi">10.47176/mjiri.38.60</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195120</ArticleId><ArticleId IdType="pubmed">32298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J. et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258639</ArticleId><ArticleId IdType="pubmed">32275452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors associated with mortality in COVID-19 patients: a systematic review and meta-analysis. Iran J Public Health. 2020;49(7):1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7548487</ArticleId><ArticleId IdType="pubmed">33083287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P. et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069–1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from a meta-analysis. Aging. 2020;12(7):6049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185114</ArticleId><ArticleId IdType="pubmed">32267833</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission—Br J Anaesth. 2020;125(2):e254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7183951</ArticleId><ArticleId IdType="pubmed">32381262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65:533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7246302</ArticleId><ArticleId IdType="pubmed">32451563</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri Soodejani, Hosseini S, Sefidkar R, Madadizadeh F, Fallahzadeh H, Dehghan A. et al. Comorbidity and its Impact on Mortality of COVID-19 in Yazd Province, a Central Part of Iran: a Hospital-Based Study. JCHR. 2022;11(2):137–141.</Citation></Reference><Reference><Citation>Shadnoush M, Rabizadeh S, Esteghamati A, Nakhjavani M, Paridari NB, Khoshabi M, Rajab A, Ghaemi F. COVID-19 infection mortality risk in Iranian patients with type 2 diabetes, hypertension and obesity. East Mediterr Health J. 2022 Mar 29;28(3):221–224.</Citation><ArticleIdList><ArticleId IdType="pubmed">35394054</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur M. Institute for health metrics and evaluation. Nursing Standard. 2014;28(42):32.</Citation></Reference><Reference><Citation>Chen Z, Peto R, Zhou M, Iona A, Smith M, Yang L. et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies. Lancet. 2015;386(10002):1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691901</ArticleId><ArticleId IdType="pubmed">26466050</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata Journal. 2013;13(3):492–509.</Citation></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis. Arch Bone Jt Surg. 2020;8(Suppl 1):247–255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296605</ArticleId><ArticleId IdType="pubmed">32733980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q. et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020;127:104371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195434</ArticleId><ArticleId IdType="pubmed">32315817</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52(6):1193–1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103107</ArticleId><ArticleId IdType="pubmed">32222883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382(26):2582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shi Z, Zhang Y, Wang C, Moreira NCDV, Zuo H. et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis. Diabetes Res Clin Pract. 2020;166:108346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375287</ArticleId><ArticleId IdType="pubmed">32710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V. et al. Is diabetes mellitus associated with mortality and severity of COVID-19. A meta-analysis. Diabetes Metab Syndr. 2020;14(4):535–545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200339</ArticleId><ArticleId IdType="pubmed">32408118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S. et al. Severe obesity, increasing age, and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228874</ArticleId><ArticleId IdType="pubmed">32422233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110296</ArticleId><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. et al. We are presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H. et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single-center study. J Clin Virol. 2020;127:104378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172806</ArticleId><ArticleId IdType="pubmed">32353762</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>